Analysts Offer Insights on Healthcare Companies: Agile Therapeutics (NASDAQ: AGRX), Ampliphi Biosciences (AMEX: APHB) and Ignyta Inc (NASDAQ: RXDX)

By Carrie Williams

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agile Therapeutics (NASDAQ: AGRX), Ampliphi Biosciences (AMEX: APHB) and Ignyta Inc (NASDAQ: RXDX) with bullish sentiments.

Agile Therapeutics (NASDAQ: AGRX)

In a report released today, Chiara Russo from Cantor Fitzgerald reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX), with a price target of $18. The company’s shares opened today at $6.86.

Russo said:

“Early this morning, AGRX announced the receipt of ~$3M in non-dilutive funding from converting unused Net Operating Loss (NOL) carryovers via the New Jersey Technology Business Tax Certificate Transfer Program. The addition of $3M, in our calculation, keeps their cash value through year- end at ~$50M, which should fund operations through 2017. This is the second time AGRX has used the program, converting ~$6M in Dec.”

According to TipRanks.com, Russo is ranked 0 out of 5 stars with an average return of -4.2% and a 39.0% success rate. Russo covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Axsome Therapeutics Inc, and Flexion Therapeutics.

Agile Therapeutics has an analyst consensus of Moderate Buy.

Ampliphi Biosciences (AMEX: APHB)

In a report released yesterday, Joseph Pantginis from Roth Capital reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $10. The company’s shares opened today at $0.52, close to its 52-week low of $0.48.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -12.5% and a 33.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Ampliphi Biosciences has an analyst consensus of Moderate Buy.

Ignyta Inc (NASDAQ: RXDX)

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Ignyta Inc (NASDAQ: RXDX) today and set a price target of $18. The company’s shares opened today at $6.30.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 2.9% and a 44.0% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Corvus Pharmaceuticals Inc, and Axsome Therapeutics Inc.

Currently, the analyst consensus on Ignyta Inc is Strong Buy and the average price target is $14.50, representing a 130.2% upside.

In a report issued on November 21, Piper Jaffray also reiterated a Buy rating on the stock with a $20 price target.